Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis

Overview

Journal Cardiovasc Intervent Radiol

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 11

PMID 38605220

Authors

Zhuofan Deng

Wenfeng Zhang

Junwei Peng

Linxiao Gao

Chunyu Zhang

Kai Lei

Jianping Gong

Bin Xiong

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aims to evaluate the prognostic value of controlling nutritional status (CONUT) score in determining the prognosis of patients with hepatocellular carcinoma (HCC) treated with conventional transcatheter arterial chemoembolization (cTACE).

Methods: This study retrospectively analyzed 936 patients who underwent cTACE for HCC between January 2012 and December 2018, and divided them into two groups based on their CONUT score. To balance the bias in baseline characteristics, propensity score matched (PSM) analysis was conducted. The Kaplan-Meier method was used to establish a cumulative survival curve, and the log-rank test was employed to determine differences in overall survival (OS) and progression-free survival (PFS) among the CONUT score groups. Furthermore, the Cox proportional hazard model was employed to assess the correlation between CONUT score and OS and PFS, whereby hazard ratios (HRs) and 95% confidence intervals (95% CIs) were computed.

Results: Before PSM, the median OS for the low (≤ 3) and high (≥ 4) CONUT group (558 vs. 378 patients) was 21.7 and 15.6 months, respectively, and the median PFS was 5.7 and 5 months. Following PSM, both the low and high CONUT score groups comprised 142 patients. The low CONUT score group exhibited a significantly longer OS compared to the high CONUT score group, as determined by the log-rank test (median OS 22.2 vs. 17.0 months, P = 0.014). No significant association was observed between CONUT group and PFS (median PFS 6.4 vs. 4.7 months, log-rank test, P = 0.121). Cox proportional hazard regression analysis revealed that a CONUT score of ≥ 4 was an independent risk factor for OS in patients with HCC who underwent cTACE (HR = 1.361; 95% CI: 1.047-1.771; P = 0.022). These findings were consistent across most subgroup analyses.

Conclusion: A high CONUT score has been found to be a prognostic factor for poorer OS in patients with HCC who underwent cTACE.

Level Of Evidence: Level 3, Non-randomized controlled cohort.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Wang W, Wu Q, Yang J, Dong K, Chen X, Bai X . Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. BMJ. 2020; 371:m4704. PMC: 7736995. DOI: 10.1136/bmj.m4704. View

Piscaglia F, Ogasawara S . Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018; 7(1):104-119. PMC: 5892363. DOI: 10.1159/000485471. View

Golfieri R, Bargellini I, Spreafico C, Trevisani F . Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer. 2019; 8(2):78-91. PMC: 6465743. DOI: 10.1159/000489791. View

Lee I, Hung Y, Liu C, Lee R, Su C, Huo T . A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019; 39(9):1704-1712. DOI: 10.1111/liv.14194. View

Kim J, Shim J, Lee H, Sung K, Ko H, Ko G . New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017; 37(12):1861-1868. DOI: 10.1111/liv.13487. View

Hung Y, Lee I, Chi C, Lee R, Liu C, Chiu N . Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer. 2021; 10(6):629-640. PMC: 8647089. DOI: 10.1159/000517393. View

de Ulibarri J, Gonzalez-Madrono A, de Villar N, Gonzalez P, Gonzalez B, Mancha A . CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005; 20(1):38-45. View

Harimoto N, Yoshizumi T, Inokuchi S, Itoh S, Adachi E, Ikeda Y . Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study. Ann Surg Oncol. 2018; 25(11):3316-3323. DOI: 10.1245/s10434-018-6672-6. View

10.

Kuroda D, Sawayama H, Kurashige J, Iwatsuki M, Eto T, Tokunaga R . Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer. 2017; 21(2):204-212. DOI: 10.1007/s10120-017-0744-3. View

11.

Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H . Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2019; 99(1):113-119. DOI: 10.1007/s00277-019-03844-2. View

12.

Yilmaz A, Tekin S, Bilici M, Yilmaz H . The Significance of Controlling Nutritional Status (CONUT) Score as a Novel Prognostic Parameter in Small Cell Lung Cancer. Lung. 2020; 198(4):695-704. DOI: 10.1007/s00408-020-00361-2. View

13.

Lin Z, Ruan D, Jia C, Wang T, Cheng J, Huang H . Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy. Clin Transl Oncol. 2019; 22(3):370-380. DOI: 10.1007/s12094-019-02137-4. View

14.

Peng W, Yao M, Zou K, Li C, Wen T, Sun X . Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study. BMC Surg. 2021; 21(1):338. PMC: 8422699. DOI: 10.1186/s12893-021-01334-9. View

15.

Chen Y, Zhao C, Yang Y, Xin Y, Wang Y, Li X . Using the Controlling Nutritional Status (CONUT) Score for Evaluating Patients with Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation: A Two-Center Retrospective Study. Cardiovasc Intervent Radiol. 2020; 43(9):1294-1304. DOI: 10.1007/s00270-020-02519-0. View

16.

Muller L, Hahn F, Mahringer-Kunz A, Stoehr F, Gairing S, Foerster F . Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. Front Oncol. 2021; 11:696183. PMC: 8225326. DOI: 10.3389/fonc.2021.696183. View

17.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

18.

Tsunematsu M, Haruki K, Fujiwara Y, Furukawa K, Onda S, Matsumoto M . Preoperative controlling nutritional status (CONUT) score predicts long-term outcomes in patients with non-B non-C hepatocellular carcinoma after curative hepatic resection. Langenbecks Arch Surg. 2020; 406(1):99-107. DOI: 10.1007/s00423-020-01987-9. View

19.

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

20.

Li S, Cao D, He J, Lou M, Tu X, Li Y . High platelet count predicts poor prognosis in HCC patients undergoing TACE: a propensity score-matched analysis. Expert Rev Gastroenterol Hepatol. 2022; 16(2):193-199. DOI: 10.1080/17474124.2022.2031977. View